FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2121787584> ?p ?o ?g. }

• W2121787584 endingPage "e1000592" @default.
• W2121787584 startingPage "e1000592" @default.
• W2121787584 abstract "Human immunodeficiency virus type 1 (HIV-1) is a chronically replicating lentivirus that must escape from adaptive immune responses that arise during the course of infection. Viral persistence is maintained by the rapid rate of HIV-1 replication and the error-prone reverse transcription of the viral genome, which produces viral variants that continually escape antibody and cytotoxic T cell responses [1]–[3]. Antibodies directed against the gp120 and gp41 components of the viral envelope glycoprotein (Env) develop within the first few weeks of infection [4],[5], but antibodies that can neutralize the infecting virus (NAbs) are usually not detected until more than 12 weeks after HIV-1 infection [6]. Thus, in natural HIV-1 infection, NAbs are not believed to play a major role in containing the acute phase of HIV-1 replication. However, several studies have shown that once NAbs arise, they exert immune selection pressure on the viral quasispecies [7]–[14].Viral escape from autologous NAbs was first described in lentiviral infections of several animal species [15]–[17]. For example, the successive waves of viremia in horses caused by equine infectious anemia virus are thought to be due to the sequential development of viral variants that temporarily evade the host NAb response. HIV-1 escape from autologous NAbs was first described in the early 1990s [18]–[20]. Subsequently, numerous research groups showed that plasma antibodies from a time point contemporaneous with viral isolation did not neutralize the autologous virus, and that NAbs against the isolated virus developed only months later [7]–[14],[21],[22]. Thus, the NAb response continually lags behind viral replication. The initial studies of NAb escape were limited by the inefficiency of isolating replication competent HIV-1 from patient plasma or lymphocytes. The more recently performed studies used molecularly cloned Env-pseudoviruses to more robustly study the plasma viral quasispecies at sequential time points. These data confirmed that, at any given time point during the course of HIV-1 infection, the circulating quasispecies of viral variants is resistant to the circulating plasma NAb. At first glance, these findings might suggest that HIV-1 should become progressively more resistant to neutralization over time. Interestingly, this is not the case. HIV-1 isolates that are resistant to circulating autologous NAbs generally remain sensitive to neutralization by several known monoclonal antibodies (mAbs) or by heterologous plasma obtained for other individuals with HIV-1. This has led to several key questions related to autologous virus NAb escape: What are the Env epitopes targeted by early autologous NAbs and how does the virus escape from these NAbs? How does continuous neutralization escape occur without leading to global changes in viral neutralization sensitivity? Finally, what are the implications of NAb escape for HIV-1 vaccines?In this issue of PLoS Pathogens, two teams of investigators provide some initial answers to these questions [23],[24]. Both groups utilized clinical samples collected from seroconversion cohorts of individuals with subtype C HIV-1. The investigators studied the development of the autologous NAb response from the acute phase, though the first 2 years of infection. A limiting dilution PCR methodology was used to clone and study HIV-1 variants from sequential plasma samples over time. Moore and colleagues studied four individuals and found that the early NAb response was restricted to two epitopes on the HIV-1 Env. They used chimeric viral clones and site-specific mutagenesis to define an epitope composed of the first and second variable region (V12) of the HIV-1 Env. A second epitope was identified within a variable alpha-2 helix region of Env that is just past the V3 loop. The restricted nature of the autologous NAb response to variable Env regions is an important finding, because it helps to explain how the virus can readily mutate to evade the NAb response. The V12 region in particular can tolerate insertions and deletions of amino acid residues without sacrificing Env function. In addition, specific amino acid changes and alterations in glycosylation in these two epitopes were found to be associated with neutralization escape. In one individual, the development of a NAb response to the alpha-2 helix region was associated with a 7-fold drop in plasma viremia, and a 4-fold rebound as neutralization escape occurred. Rong and colleagues similarly studied longitudinal samples from two individuals and found a highly restricted set of NAbs. They also identified the V12 region as a key target of autologous NAbs. Mapping studies demonstrated that specific amino acid sequence alterations, as well as changes in the pattern of glycosylation, were important components of neutralization escape. Importantly, they were able to isolate two mAbs from one patient, and demonstrated that a single amino acid substitution affecting a glycosylation site in V2 was responsible for resistance to these mAbs. In some cases, mutations outside of the specific neutralization epitopes were also associated with neutralizing escape. Given the complex trimeric structure of the HIV-1 Env, it is well known that distant mutations can affect the conformational structure of Env and impact antibody recognition of an epitope [25]. While these two new studies have probably not described the full spectrum of autologous NAb responses, the consistent finding of an early dominant NAb response to one or two variable regions of Env that can vary without major cost to viral fitness does help explain how the virus is able to effectively evade the NAb response.The study of the early autologous NAb response adds to our understanding of the role of NAbs in natural HIV-1 infection, and has potential implications for HIV-1 vaccine design. We know that, over time, more broadly reactive NAbs develop in some individuals with HIV-1 [26]–[28]. These NAbs appear to target functionally conserved regions of Env such as the receptor or co-recpetor binding sites, or conserved regions of gp41 [27], [29]–[31]. Thus, immune escape from such NAbs would, in theory, be much more difficult [32]. In addition, these antibodies can protect against AIDS virus infection in non-human primate models [33],[34]. We still do not understand why such NAbs arise so late during the course of HIV-1 infection. Hence, investigators should continue to study the longer-term evolution of the NAb response in order to better understand the early epitope dominance of the autologous NAb response, and the clinical and virologic factors associated with the evolution from a type-restricted NAb response to a more broadly reactive response. While NAbs may arise too late during natural HIV-1 infection to have a major impact on HIV-1 replication, a major goal of vaccine researchers is to generate pre-existing NAb responses that can prevent initial HIV-1 infection, or contain the virus during the initial phase of viral dissemination [3],[26],[35],[36]. A better understanding of the evolution of the natural NAb response during natural infection, including the viral epitopes targeted, can provide insights for vaccine immunogen design." @default.
• W2121787584 created "2016-06-24" @default.
• W2121787584 creator A5071657202 @default.
• W2121787584 date "2009-09-18" @default.
• W2121787584 modified "2023-09-23" @default.
• W2121787584 title "The Cat and Mouse of HIV-1 Antibody Escape" @default.
• W2121787584 cites W1588024596 @default.
• W2121787584 cites W1602075566 @default.
• W2121787584 cites W1967083729 @default.
• W2121787584 cites W1971233211 @default.
• W2121787584 cites W1974138678 @default.
• W2121787584 cites W1979980949 @default.
• W2121787584 cites W1986103819 @default.
• W2121787584 cites W1997677784 @default.
• W2121787584 cites W1998987175 @default.
• W2121787584 cites W2000591768 @default.
• W2121787584 cites W2006483986 @default.
• W2121787584 cites W2008318582 @default.
• W2121787584 cites W2013330052 @default.
• W2121787584 cites W2013974444 @default.
• W2121787584 cites W2029043430 @default.
• W2121787584 cites W2034160159 @default.
• W2121787584 cites W2050043091 @default.
• W2121787584 cites W2076366830 @default.
• W2121787584 cites W2084310667 @default.
• W2121787584 cites W2085166312 @default.
• W2121787584 cites W2087831927 @default.
• W2121787584 cites W2096699901 @default.
• W2121787584 cites W2105903892 @default.
• W2121787584 cites W2108868448 @default.
• W2121787584 cites W2111914135 @default.
• W2121787584 cites W2113783843 @default.
• W2121787584 cites W2116983636 @default.
• W2121787584 cites W2124935744 @default.
• W2121787584 cites W2126654882 @default.
• W2121787584 cites W2127146638 @default.
• W2121787584 cites W2127249709 @default.
• W2121787584 cites W2137939749 @default.
• W2121787584 cites W2140927222 @default.
• W2121787584 cites W2147915261 @default.
• W2121787584 cites W2155134568 @default.
• W2121787584 cites W4248734872 @default.
• W2121787584 doi "https://doi.org/10.1371/journal.ppat.1000592" @default.
• W2121787584 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2742737" @default.
• W2121787584 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19763273" @default.
• W2121787584 hasPublicationYear "2009" @default.
• W2121787584 type Work @default.
• W2121787584 sameAs 2121787584 @default.
• W2121787584 citedByCount "11" @default.
• W2121787584 countsByYear W21217875842012 @default.
• W2121787584 countsByYear W21217875842013 @default.
• W2121787584 countsByYear W21217875842014 @default.
• W2121787584 countsByYear W21217875842017 @default.
• W2121787584 countsByYear W21217875842018 @default.
• W2121787584 crossrefType "journal-article" @default.
• W2121787584 hasAuthorship W2121787584A5071657202 @default.
• W2121787584 hasBestOaLocation W21217875841 @default.
• W2121787584 hasConcept C159047783 @default.
• W2121787584 hasConcept C159654299 @default.
• W2121787584 hasConcept C185592680 @default.
• W2121787584 hasConcept C203014093 @default.
• W2121787584 hasConcept C3013748606 @default.
• W2121787584 hasConcept C86803240 @default.
• W2121787584 hasConcept C95444343 @default.
• W2121787584 hasConceptScore W2121787584C159047783 @default.
• W2121787584 hasConceptScore W2121787584C159654299 @default.
• W2121787584 hasConceptScore W2121787584C185592680 @default.
• W2121787584 hasConceptScore W2121787584C203014093 @default.
• W2121787584 hasConceptScore W2121787584C3013748606 @default.
• W2121787584 hasConceptScore W2121787584C86803240 @default.
• W2121787584 hasConceptScore W2121787584C95444343 @default.
• W2121787584 hasIssue "9" @default.
• W2121787584 hasLocation W21217875841 @default.
• W2121787584 hasLocation W21217875842 @default.
• W2121787584 hasLocation W21217875843 @default.
• W2121787584 hasLocation W21217875844 @default.
• W2121787584 hasLocation W21217875845 @default.
• W2121787584 hasOpenAccess W2121787584 @default.
• W2121787584 hasPrimaryLocation W21217875841 @default.
• W2121787584 hasRelatedWork W1487857142 @default.
• W2121787584 hasRelatedWork W1702322095 @default.
• W2121787584 hasRelatedWork W1865764402 @default.
• W2121787584 hasRelatedWork W1945359667 @default.
• W2121787584 hasRelatedWork W1975114493 @default.
• W2121787584 hasRelatedWork W1984647379 @default.
• W2121787584 hasRelatedWork W2089394918 @default.
• W2121787584 hasRelatedWork W2118087741 @default.
• W2121787584 hasRelatedWork W2163895276 @default.
• W2121787584 hasRelatedWork W4253675151 @default.
• W2121787584 hasVolume "5" @default.
• W2121787584 isParatext "false" @default.
• W2121787584 isRetracted "false" @default.
• W2121787584 magId "2121787584" @default.
• W2121787584 workType "article" @default.